460 results on '"Kirschbaum, Mark"'
Search Results
2. The pharmacy community apgar questionnaire: A modified Delphi technique to develop a rural pharmacist recruitment and retention tool
3. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
4. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
5. Correction to: Factors contributing to the recruitment and retention of rural pharmacist workforce: a systematic review
6. Factors contributing to the recruitment and retention of rural pharmacist workforce: a systematic review
7. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
8. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
9. DNA Methylation and Epigenetics: New Developments in Biology and Treatment
10. Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
11. Supplemenary Figure 2 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
12. Supplemenary Figure 4 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
13. Supplementary Figure 5 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
14. Supplemental Figures 1 and 2 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
15. Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
16. Supplemenary Figure 7 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
17. Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
18. Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
19. Supplementary Figure Legends from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
20. Table from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
21. Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
22. Data from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
23. Supplementary Figure 1 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
24. Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
25. Supplementary Methods from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
26. Data from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
27. Supplementary Figure Legends for Table 1 and Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
28. Supplementary Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
29. Data from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
30. Supplementary Table 1 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
31. Pharmacy students’ rural career intentions: Perspectives on rural background and placements
32. Mental health first aid training needs of Australian community pharmacists
33. Clinical placements by Australian university schools of pharmacy
34. Sustaining rural pharmacy workforce understanding key attributes for enhanced retention and recruitment
35. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
36. When scabies presents at the pharmacy
37. Adverse drug reactions in primary care: a scoping review protocol
38. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study
39. The influence of lateral topographic confinement on fluvial channel‐belt clustering, compensation and connectivity – lower Wasatch Formation and Dakota Sandstone, Utah, USA
40. Oncogenic Receptor Tyrosine Kinases
41. Sustaining rural pharmacy workforce understanding key attributes for enhanced retention and recruitment.
42. A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation
43. HDAC Inhibitor Reduces Cytokine Storm and Facilitates Induction of Chimerism That Reverses Lupus in Anti-CD3 Conditioning Regimen
44. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
45. Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia
46. Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors
47. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
48. Be our guest: Health literacy in pharmacy
49. Additional file 4 of Factors contributing to the recruitment and retention of rural pharmacist workforce: a systematic review
50. Additional file 1 of Factors contributing to the recruitment and retention of rural pharmacist workforce: a systematic review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.